Liver, Gallbladder, and Biliary Tract Cancers

Liver, Gallbladder, and Biliary Tract Cancers

Results from a phase I/II study suggest that the immunotherapy nivolumab is safe and effective in advanced hepatocellular carcinoma (HCC).

Aflatoxin, a naturally occurring toxin produced by certain types of molds, has been found to be associated with an increased risk of gallbladder cancer.

Current use of statins was associated with about a 50% decreased risk for liver cancer, according to results of a study looking at data from the United Kingdom.

A recent study found that radiation therapy was effective for the palliation of painful spinal metastases in patients with hepatocellular carcinoma.

Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.

In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.

The addition of cediranib to treatment with cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer, according to the results of the phase II ABC-03 trial.


Subscribe to Liver, Gallbladder, and Biliary Tract Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.